Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 207

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 207
---
ability                             |     |      | A-50 |
| 9.7  Obligation of Parent                     |     |      | A-50 |
| 9.8  No Third Party Beneficiaries             |     |      | A-50 |
| 9.9  No Liability                             |     |      | A-50 |
| 9.10 Entire Agreement                         |     |      | A-50 |
| 9.11 Equitable Remedies                       |     |      | A-51 |
| 9.12 Assignment                               |     |      | A-51 |
| 9.13 Governing Law and Jurisdiction           |     |      | A-51 |
| 9.14 Counterparts                             |     |      | A-52 |
| 9.15 Certain Assurances                       |     |      | A-52 |
| 9.16 Language                                 |     |      | A-52 |

A-3

ARRANGEMENT AGREEMENT

THIS AGREEMENT (“Agreement”) made as of the 14th day of November, 2025

BETWEEN:

XENOTHERAPEUTICS, INC., a
company existing under the laws of Massachusetts,

(hereinafter called “Parent”)

- and -

XENO ACQUISITION CORP., a company existing under the laws of Delawareand a wholly-owned subsidiary of Parent,

(hereinafter called the
“Purchaser”)

- and -

REPARE THERAPEUTICS INC., a company existing under the laws of the Province of Québec,

(hereinafter called the “Company”)

- and -

solely for purposes of Section9.15, XOMA ROYALTY CORPORATION, a company existing under the laws of Nevada,

(hereinafter called
“XRC”)

WHEREASthe Purchaser wishes to acquire all of the issued and outstanding Common Shares (as hereinafter defined) in the
capital of the Company by way of a plan of arrangement under the provisions of the QBCA (as hereinafter defined), on the terms and subject to the conditions set forth in this Agreement;

AND WHEREASthe board of directors of the Company (the “Board of Directors” or “Board”), after consultation with
its financial and legal advisors and receiving recommendations from a transaction committee of the Board of Directors (the